A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers
Kim A. Reiss(University of Pennsylvania), Nilofer S. Azad(Johns Hopkins Hospital), Naomi Horiba(University of Maryland, Baltimore), Laura A. Dawson(Princess Margaret Cancer Centre), Alice P. Chen(National Institutes of Health), Sarah M. Temkin(Anne Arundel Medical Center), Amy Hacker‐Prietz(Sidney Kimmel Comprehensive Cancer Center), Marianna Zahurak(Bloomberg (United States)), Michael Milosevic(Princess Margaret Cancer Centre), Lee-Anne Stayner(University Health Network), Anthony Brade(Princess Margaret Cancer Centre), Anthony Fyles(University Health Network), Joseph M. Herman(Northwell Health), Deborah K. Armstrong(Johns Hopkins University), Robert J. Kinders(National Cancer Institute), Angela Scardina(Sidney Kimmel Comprehensive Cancer Center), Lihua Wang(National Cancer Institute), Patricia Fischer(Johns Hopkins Hospital), Lillian L. Siu(University Health Network)
Cited by 53
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k